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Integrin α5β1 is a crucial adhesion molecule that mediates the adherence of many cell
types to the extracellular matrix through recognition of its classic ligand fibronectin as well
as to other cells through binding to an alternative counter-receptor, the metalloproteinase
ADAM17/TACE. Interactions between integrin α5β1 and ADAM17 may take place both
in trans (between molecules expressed on different cells) or in cis (between molecules
expressed on the same cell) configurations. It has been recently reported that the cis
association between α5β1 and ADAM17 keeps both molecules inactive, whereas their
dissociation results in activation of their adhesive and metalloproteinase activities. Here
we show that the tetraspanin CD9 negatively regulates integrin α5β1-mediated cell
adhesion by enhancing the cis interaction of this integrin with ADAM17 on the cell surface.
Additionally we show that, similarly to CD9, themonoclonal antibody 2A10 directed to the
disintegrin domain of ADAM17 specifically inhibits integrin α5β1-mediated cell adhesion
to its ligands fibronectin and ADAM17.
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INTRODUCTION
Integrins constitute an important family of heterodimeric (αβ) cellular receptors which, upon
recognition and binding to specific ligands, mediate the adhesion of cells to components of
the extracellular matrix (such as fibronectin, laminin, collagens) as well as cell-cell adhesion
phenomena with crucial relevance in a variety of physiological and pathophysiological processes
[reviewed in (1–3)]. Integrin α5β1 (also termed CD49e/CD29 or VLA5) binds to its canonical
ligand fibronectin (Fn) through recognition of the Arg-Gly-Asp (RGD)motif in Fn-type-IIImodule
10 and of a synergy site in Fn-type-III module 9, contributing to fibronectin assembly into fibrils
(4). In addition tomediating cell adhesion through binding to its canonical Fn ligand, integrin α5β1
also has been reported to specifically recognize and bind to an alternative ligand, the disintegrin
domain of ADAM17 (5–7).
ADAMs (A Disintegrin And Metalloproteinase) are a family of type-I transmembrane proteins
with a modular structure that comprises the following domains (from N- to C-termini): a pro-, a
Machado-Pineda et al. CD9 Reinforces Integrin α5β1-ADAM17 Association
catalytic-, a disintegrin-, a cysteine-rich-, and an EGF-like-
domain, followed by a transmembrane- and a cytoplasmic region.
40 ADAMs have been identified in the mammalian genome
from various species with the human genome containing 21
functional ADAMs, of which only 13 are proteolytically active
while the rest lack the Zn-binding motif in the catalytic domain
which is required for the proteolytic activity [reviewed in (8–
10)]. Two closely related members of this family, ADAM10
and ADAM17, stand out among the catalytically active ADAMs
as they are the two main cellular enzymes responsible for the
cleavage and release of ectodomains from many cell surface
proteins, a process known as “shedding” which plays an essential
role in the development of tissues and organisms and in many
other physiological as well as pathophysiological processes (11).
ADAM10 and ADAM17 are also considered atypical members of
the ADAM family since the extracellular cysteine-rich and EGF-
like domains found in the rest of ADAMs are replaced in these
two enzymes by a unique membrane proximal domain (MPD),
which is involved in substrate recognition and binding as well as
in regulation of their shedding activity [reviewed in (12, 13)].
All ADAMs contain a disintegrin domain in their extracellular
region, which is structurally related to snake venom disintegrins.
The disintegrin domains of ADAMs can potentially act as ligands
for integrin binding, thus influencing cell adhesion and cell-cell
interactions, with some degree of selectivity existing for these
interactions between specific members of integrin and ADAM
families (12–14).
Interactions of α5β1 with ADAM17 may occur among
molecules expressed on the same cell (cis) or on different cells
(trans), with the latter reported to support cell-cell adhesion
events (6, 13). Interestingly, the interaction between integrin
α5β1 and the disintegrin domain of ADAM17 has been shown to
cause the inhibition of both the adhesive capacity of the integrin
(i.e., its ability to bind its ligands) as well as that of ADAM17
metalloproteinase activity due to steric hindrance leading to
decreased accessibility of its catalytic site for the substrates (6,
13). In contrast, stimuli that promote the dissociation of the
α5β1-ADAM17 complex, such as an excess of soluble ADAM17
disintegrin domain, induce the activation of ADAM17 sheddase
activity and enhance integrin adhesive capacity (6, 13).
The tetraspanin CD9, within the context of tetraspanin-
enriched microdomains (TEMs), has been reported to associate
on the cell surface with different adhesion receptors of the
immunoglobulin and integrin families (15), including the
integrin α5β1 (16–18). Through these interactions, CD9 exerts
different regulatory effects on the function of associated adhesion
molecules (19–23). On the other hand, CD9 also has been
reported to associate directly with ADAM17 on the surface of
different types of cells, thus exerting an inhibitory effect on
ADAM17 sheddase activity against a variety of its substrates
(19, 24–27).
Here we report that integrin α5β1 mediates the specific
adhesion of different tumoral and leukocytic cells to immobilized
recombinant ADAM17-Fc protein, which can be efficiently
abrogated with blocking mAbs directed against the α5 or
the β1 subunits of the integrin. Interestingly, the expression
of CD9 on the cell surface or preincubation with mAb
2A10, which is directed to the disintegrin domain of human
ADAM17, also abrogated the α5β1-mediated adhesion both to
its canonical ligand Fn and to ADAM17-Fc. In situ proximity
ligation assays (PLA) and biochemical experiments based on co-
immunoprecipitation collectively revealed that the mechanism
by which CD9 and mAb 2A10 inhibit α5β1-mediated cell
adhesion is related to the reinforcement of cis interactions
between ADAM17 and α5β1 on the cell surface, which takes
place without alteration in α5β1 integrin affinity but is rather
evidenced by changes in the organization of integrin molecules
at the plasma membrane.
MATERIALS AND METHODS
Generation of mAB 2A10 Against the
Disintegrin Domain of Human ADAM17
The mAb 2A10 was generated after mice immunization with the
recombinant chimeric protein ADAM17-Fc, which encompasses
the whole extracellular region of human ADAM17 fused to the
Fc fragment of human IgG1, by employing the standard murine
hybridoma technology. The experimental protocol followed was
in accordance with the National Institutes of Health Guide for
Care and Use of Laboratory Animals and was approved by the
Animal Ethics Committee of the “Centro de Biología Molecular
Severo Ochoa” (Madrid, Spain). The 2A10 mAb was selected
from among the several hundred hybridomas generated based
on its high and specific reactivity against ADAM17-Fc in ELISA
assays. Assessment of the reactivity of 2A10 mAb against purified
disintegrin (Dis) and membrane-proximal (MP) domains of
human ADAM17, revealed that the epitope recognized by this
mAb maps to the disintegrin domain.
Cells and Antibodies
Raji (Burkitt’s lymphoma-derived B lymphoblastoid), JY (EBV-
immortalized B lymphoblastoid), K562 (erythroblastic cell line),
HSB2 (T lymphoblastic), Jurkat (T lymphoblastic), and Colo320
(colorectal adenocarcinoma) human cell lines were cultured in
RPMI-1640. SKOV-3 (ovarian carcinoma) human cell line was
grown in DMEM. LoVo (colorectal adenocarcinoma) human cell
line was cultured in DMEM supplemented with F-12 nutrient
mixture. All culture media were supplemented with 10% heat-
inactivated FBS, 2mM glutamine, 50µg/ml streptomycin and 50
U/ml penicillin.
2A10 (anti-ADAM17); P1D6 (anti-α5 integrin) (28); TS2/16
(anti-β1 integrin), Lia1/2 (anti-β1 integrin) (29, 30), and
HUTS21 (anti-β1 integrin) (31); TS1/18 (anti-β2 integrin) (32);
PAINS-10 (anti-CD9) (33) and MEM-111 (anti-ICAM1/CD54)
(34) mAbs were purified by protein A- or protein G-affinity
chromatography. The A300D (specific for the disintegrin domain
of human ADAM17) and A300E (specific for the membrane
proximal domain of human ADAM17) mAbs have been
described previously (35). When necessary, purified mAbs were
biotinylated as previously described (33).
Expression DNA Constructs and
CRISPR/Cas9-Mediated Gen Knock Out
For stable transfection experiments, Colo320 and HSB2 cells
were incubated in 2.5% FCS–RPMI-1640 with the cDNA (20
µg) coding for human CD9 (in the pcDNA3 expression vector).
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Colo320 cells were electroporated at 412 V/cm and HSB2 cells at
200 V/cm (2 × 10ms pulses in a 0.4 cm electroporation cuvette)
in the ElectroSquarePorator ECM830 (BTX, Holliston,MA),
positive clones were selected with G418 (0.8mg/ml) in the culture
medium (20).
To generate “Colo320-CRISPR ADAM17” and “Jurkat-
CRISPR CD9” cell lines, cells were transfected with the
CRISPR/Cas9 knockout plasmid pX461 encoding GFP and Cas9
nickase and the following sequences to generate the specific
single guide RNAs: 5′-CACCGATCTAATATCCAGCAGCATT-
3′ and 5′-CACCGTTTTTCTTACCGAATGCTGC-3′ for
ADAM17 and 5′-CACCGTTCTTGCTCGAAGATGCTCT-3′
and 5′-CACCGGAATCGGAGCCATAGTCCAA-3′ for CD9.
Transfected cells were sorted by flow cytometry based on their
GFP transient fluorescence and then expanded and checked for
suppression of ADAM17 or CD9 expression.
Flow Cytometry Analysis
For flow cytometry analysis of protein surface expression cells
were washed three times in RPMI-1640, incubated with primary
antibodies at 4◦C for 30min followed by Alexa Fluor R©647-
conjugated anti-mousse IgG and fixed in 2% formaldehyde
in PBS. Changes in integrin affinity were probed with the
anti-β1 integrin activation reporter HUTS21 mAb. Cells were
washed in cation-free medium (Hepes 20mM, NaCl 149mM, 2
mg/ml glucose) and incubated for 20min at 37◦C with Mn2+
(400µM) or with Ca2+/Mg2+ (0.5 mM/1mM, respectively)
in the presence of biotinylated HUTS21 mAb. Cells were
then washed and stained with Alexa Fluor R©488-conjugated
streptavidin. Fluorescence was measured using a FACScan
TM
flow cytometer (Beckton-Dickinson).
Immunofluorescence, Proximity Ligation
Assays and Confocal Microscopy
For double immunofluorescence studies, cells were seeded on
12-mm diameter glass coverslips coated with poly-L-lysine
(100µg/ml). Cells were fixed in 2% formaldehyde (8min at
room temperature), blocked in 1% BSA in TBS (30min at room
temperature), and incubated for 1h with mAb 2A10 (10µg/ml),
followed by washes and incubation with the secondary antibody
Alexa Fluor
TM
-647-conjugated anti-mousse IgG (Thermo-Fisher
Scientific). After incubation for 1 h with mouse serum (1/100)
to block any free Fab binding sites of the secondary antibody,
samples were incubated for 1 h with biotinylated-TS2/16 mAb
(10µg/ml), then with the secondary reagent streptavidin-
Alexa Fluor
TM
-488 (Life Technologies) and finally mounted on
microscope slides with Fluoromount
TM
/DAPI (Sigma-Aldrich).
In situ proximity ligation assays (PLA; Duolink kit, Sigma
Aldrich) allows detection of direct protein–protein interactions
in cell samples by fluorescence microscopy (36). Colo320
cells were seeded, fixed and blocked as described above.
Next, samples were incubated simultaneously with 2A10 (anti-
ADAM17) mouse mAb and with an anti-α5 rabbit polyclonal
antibody, followed by specific oligonucleotide-labeled secondary
antibodies (anti-mouse plus and anti-rabbit minus probes). Only
if the two target proteins are in close proximity (≤40 nm),
the oligonucleotides of the two probes will hybridize and after
a rolling-circle amplification reaction and detection with a
different fluorescently labeled oligonucleotide, fluorescent dot
signals can be visualized by microscopy. Samples were mounted
with ProLong R© anti-fade reagent and images were obtained
with a Leica LSM510 inverted confocal microscope. Fiji/Image-J
software was used for detection and analysis of fluorescent dots.
Co-immunoprecipitation
Co-immunoprecipitation experiments were performed using
intact cells, in order to detect only surface protein–protein
interactions. Cells were incubated for 1 h at RT with the anti-β1
mAb Lia1/2 or the anti-CD9 mAb PAINS-10 in the presence of
Ca2++Mg2+ (500µM + 500µM) or Mn2+ (200µM), followed
by washing the non-bound antibody excess. Cells were then lysed
for 15min at 4◦C in TBS containing 1% Brij-97 in the presence of
corresponding extracellular cations and protease inhibitors and,
after removal of insoluble material, incubated for 4 h at 4 ◦C with
protein A-sepharose. Beads were then washed with 1:5 diluted
lysis buffer, boiled in nonreducing (for detection of CD9 and
β1 integrin) or reducing (for detection of ADAM17) Laemmli
buffer, resolved by 8% or 12% SDS-PAGE and transferred
onto nitrocellulose membranes. Membranes were blocked with
3% BSA and developed either with biotinylated anti-CD9
mAb PAINS10 or biotinylated anti-β1 mAb TS2/16 or anti-
ADAM17 mAb A300D, followed by incubation respectively
with streptavidin-HRP (Thermo-Fisher Scientific) or anti-
mouse IgG-HRP (Sigma-Aldrich) secondary reagents and ECL-
chemiluminescence detection on an ImageQuant LAS4000-mini
system.
Cell Adhesion Assays
Static cell adhesion to ADAM17-Fc, ICAM1-Fc or fibronectin-
coated wells was performed as described previously (19, 37). 96-
well flat-bottom plates were pre-coated overnight at 4◦C with
ADAM17-Fc (20µg/ml), ICAM1-Fc (20µg/ml) or fibronectin
(7.5µg/ml) and blocked for 2 h with 1% BSA in PBS. For
PMA-stimulated cell adhesion, cells were incubated with PMA
(200 ng/ml) in RMPI-1640 for 2h at 37◦C. Cells (2 × 105
cells/well) were loaded with the fluorescent probe BCECF-AM
for 20min at 37◦C in PBS, washed, resupended in adhesion buffer
(Hepes 20mM, NaCl 149mM, 2 mg/ml glucose) containing
200 µM Mn2+, added to the wells in the presence of the
appropriate mAbs (10µg/ml) and allowed to adhere for 60min
at 37◦C.When indicated in Figure 1D, only the cells or the plates
precoated with immobilized ligands ADAM17-Fc or Fn were
incubated first with 10µg/ml of anti-ADAM17 (2A10), anti-β1
(Lia1/2), anti-α5 (PID6), or the control anti-ICAM1 (MEM-111)
mAbs for 60min at 4◦C, then the excess non-bound antibody
was washed and the cells were subsequently allowed to adhere
onto the immobilized ligand by transferring the plates to 37◦C
for 60min. After gently washing the wells several times with PBS
at 37◦C to remove non-adherent cells, the percentage of adherent
cells in each well was calculated by determining their fluorescence
in a microplate reader (TecanGENios) before and after having
removed the non-adherent cells.
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FIGURE 1 | The adhesion of different tumoral and leukocytic cells to Fn and ADAM17-Fc is specifically mediated by integrin α5β1. The adhesion of different human
cell lines derived from solid tumors (A) or hematopoietic malignancies (B) to immobilized ADAM17-Fc or to fibronectin (C) is represented. The effect of mAbs Lia1/2
(blocking anti-β1 integrin subunit), P1D6 (blocking anti-α5 integrin subunit) and mAb 2A10 (specific for the disintegrin domain of human ADAM17) on cell adhesion is
shown. The anti-ICAM1/CD54 mAb MEM 111 was included as a negative control. Data show the percentages of adherent cells (means ± SEM of at least three
different experiments, each performed in triplicates). (D) Effect of preincubating plastic-immobilized ADAM17-Fc (left graph) or Colo320 cells (right panel) with the
indicated mAbs (the excess non-bound antibody was subsequently washed away) prior to adding the cells to the ADAM-17-coated wells and allowing their adhesion
at 37◦C. In all cases, cells were stimulated with PMA (200 ng/ml) for 2 h, loaded with the fluorescent probe BCECF-AM and then allowed to adhere to
plastic-immobilized ligands ADAM17-Fc (20µg/ml) or Fn (7.5µg/ml) for 60min at 37◦C in the presence of Mn2+ (200µM). Data show the percentages of adherent
cells (means ± SEM of three experiments, performed in triplicates) relative to the 100% cell adhesion considered in the absence of antibody treatment. Data were
analyzed by one-way ANOVA with Dunnett’s post-test analysis **p < 0.01, ***p < 0.001 and ****p < 0.0001 values denote the statistical significance of differences
between a specific condition and the control condition in the absence of antibody (−).
Statistical Analysis
As indicated in the individual figure legends, different statistical
analyses of data were performed depending on the quantitative
and qualitative nature of the variables being considered. These
analyses include the two-tailed paired T-test and the one-way
ANOVA coupled with Dunnet’s, Tukey’s, or Šidák’s multiple
comparison tests.
RESULTS
Integrin α5β1 Mediates the Adhesion of
Tumoral and Leukocytic Cells to
Immobilized ADAM17
Recombinant ADAM17 has been reported to support integrin
α5β1-dependent fibroblast and kidney mesangial cell adhesion,
and such adhesion was demonstrated to occur through integrin
binding to the disintegrin domain of ADAM17 (5–7). We
decided to build on these findings by assessing whether the
adhesion of several other human cell lines derived either from
solid tumors (“cancer cell lines”) or hematological malignancies
(“leukocytic cell lines”) to immobilized recombinant ADAM17-
Fc was also mediated by integrin α5β1. Figure 1A shows
that, when stimulated with phorbol ester PMA and divalent
cation Mn2+ (a potent activating agent that induces integrin
high affinity state), Colo320 (colorectal adenocarcinoma), LoVo
(colorectal adenocarcinoma) and SKOV-3 (ovarian carcinoma)
cancer cells readily and specifically adhered to a substrate
coated with ADAM17-Fc. In all cases, adhesion of these
cells to ADAM17-Fc was specifically mediated by integrin
α5β1, as demonstrated by the potent inhibition achieved
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either with a blocking anti-α5 mAb (P1D6) or anti-β1
mAb (Lia1/2) antibodies. Likewise, the PMA/Mn2+-stimulated
adhesion of leukocytic Jurkat (T lymphoblastic) and K562
(erythroblastic) cells to ADAM17-Fc was also shown to be
fundamentally dependent on integrin α5β1 (Figure 1B). In
contrast, the leukocytic JY (EBV-immortalized B lymphoblastoid
cell line) cells, which do not express any β1-containing
integrins (including α5β1) due to the lack of expression of
this integrin chain, and Raji (Burkitt’s lymphoma-derived B
lymphoblastoid cell line) cells, which do not express integrin
α5β1 although they express abundant α4β1 (another important
Fn receptor), only displayed a negligible level of adhesion
to ADAM17-Fc (<5%), even after strong stimulation with
PMA/Mn2+.
Colo320 and K562 cells, which selectively express abundant
levels of the integrin α5β1 on their surface, also adhered
efficiently to Fn after stimulation with Mn2+ and this adhesion
was blocked by either P1D6 or Lia1/2 mAbs. However, although
JY and Raji cells also adhered very efficiently to Fn, such adhesion
was not inhibited by the blocking anti-α5 (P1D6) mAb as it was
not mediated by integrin α5β1, but rather through integrins α4β7
and α4β1, respectively (Figure 1C).
Taken together, these results concur with previous reports (5–
7) and confirm that integrin α5β1, in addition to binding to its
canonical ligand Fn, also mediates the adhesion of a wide variety
of cells to immobilized ADAM17-Fc.
The mAb 2A10 was generated in our laboratory and shown
by ELISA assays to be specific against an epitope located on the
disintegrin domain of human ADAM17 mAb (Figure 2).
We then assessed the effects of mAb 2A10 on cell adhesion to
both α5β1 ligands, ADAM17-Fc and Fn. As shown in Figure 1,
in all cases where cell adhesion was predominantly mediated
by integrin α5β1, mAb 2A10 exerted a potent inhibitory effect
on cell adhesion. In contrast, mAb 2A10 had no effect on the
adhesion of JY or Raji cells to Fn which, as indicated above, is
not mediated by α5β1. Furthermore, mAb 2A10 had no effect
on the cell adhesion mediated by integrin LFA-1 (αLβ2), clearly
showing that its effects are specifically mediated through integrin
α5β1 (Supplementary Figure 1).
The observed blockade of cell adhesion to Fn with mAb
2A10 suggested that this antibody must exert its effects on α5β1-
mediated adhesion through a cis-type mechanism after binding
to cell surface ADAM17. In any case, and to rule out a possible
steric hindrance of cell adhesion caused by binding of mAb 2A10
to the disintegrin domain of the immobilized ligand ADAM17-
Fc, we first incubated Colo320 cells with 2A10 and washed away
the excess of unbound antibody before allowing cells to adhere
onto immobilized ADAM17-Fc (Figure 1D, right panel). These
FIGURE 2 | Monoclonal antibody 2A10 is specific for the disintegrin domain of human ADAM17 (hADAM17). Assessment by ELISA of the reactivity of mAb 2A10
against the purified disintegrin domain of hADAM17 (left), the membrane-proximal domain of hADAM17 (middle) or the recombinant chimeric protein ADAM17-Fc
(right). The mAb A300D, which recognizes an epitope mapped to the disintegrin domain of human ADAM17 and the mAb A300E, which recognizes an epitope
mapped to the membrane-proximal domain of human ADAM17, were used respectively as positive controls for each of these domains. The mAb TS1/18 (anti-human
β2 integrin) and mAb MEM111 (anti-ICAM1/CD54) were used as negative controls. Graphs show the absorbance, expressed in arbitrary units, relative to the
unspecific absorbance background in the absence of antibody. Data correspond to the mean ± SEM from three independent experiments, each performed in
triplicate and analyzed by one-way ANOVA with Dunnett’s post-test analysis **p < 0.01, ***p < 0.001, ****p < 0.0001. The colored schematics underneath each panel
highlight the specific domains of hADAM17 immobilized on plastic for each ELISA assay.
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analyses confirmed that the adhesion blocking effect exerted by
mAb 2A10 was due to a regulation in cis of α5β1-mediated
adhesion.
Expression of CD9 Inhibits α5β1-Mediated
Cell Adhesion to ADAM17 and Fibronectin
We have previously shown that CD9 on the cell surface is
engaged in direct interactions with ADAM17 and through such
association inhibits ADAM17 metalloproteinase activity (19, 24,
25). Therefore, we decided to assess whether the presence or
absence of CD9 on the cell surface could influence not only
ADAM17 sheddase activity but also its regulatory effect exerted
on the adhesive activity of integrin α5β1. For this purpose, we
generated a series of paired variants derived from Jurkat, HSB2
and Colo320 cell lines, that differed in the presence/absence of
CD9 following either the neoexpression of this tetraspanin (by
stable transfection of CD9 cDNA in CD9− Colo-320 and HSB2
cells) or its supression by CRISPR/Cas9 gene knockout (in CD9+
Jurkat cells; Figure 3A). For all these three cell lines, the variants
expressing CD9 (Colo320-CD9, HSB2-CD9, Jurkat) displayed
a greatly reduced capacity to adhere to ADAM17-Fc, even in
the presence of the potent integrin stimulus Mn2+, compared
to their respective CD9− (Colo320, HSB2, Jurkat-CRISPR-CD9)
counterparts (Figure 3B). We also assessed the adhesion of these
paired cell variants to Fn and again, the presence of CD9 resulted
in reduced cell adhesion (Figure 3C), except for the case of Jurkat
cells that, in addition to α5β1, also express very high levels of the
fibronectin-binding integrin α4β1 (Figure 3A).
CD9-Induced Inhibition of α5β1-Mediated
Cell Adhesion Cannot be Attributed to
Decreased Integrin Conformational
Change to the High Affinity State
The observed abrogation of integrin α5β1-mediated cell adhesion
caused by the cell surface expression of CD9 could be due
either to diminished integrin affinity or to an alteration
in the organization of α5β1 integrin molecules on the cell
surface resulting in lower multivalent avidity for ligand. First
we investigated whether changes in the affinity of α5β1
were being induced by the presence of CD9, and for this
purpose we compared in Colo320 and Colo320-CD9 cells the
expression of the epitope HUTS21, which reports the high
affinity state—characterized by an extended and open headpiece
conformation—of integrins that contain the β1 subunit (31),
and particularly of integrin α5β1 (38, 39). Colo320/Colo320-
CD9 cells represent a very clean cellular system to assess α5β1
integrin-mediated adhesion, since they selectively express high
levels of α5β integrin, but neither α4β1 integrin nor any other
β2-associated integrins, and only very low levels -if at all- of
other major integrins (not shown). As shown in Figures 4A,B, no
significant differences in the expression of the HUTS21 epitope
between Colo320 and Colo320-CD9 cells were detected, neither
in the presence of extracellular Ca2+ and Mg2+, which resemble
resting physiological conditions in terms of integrin activation, or
under conditions which fully induce the acquisition of integrin
high affinity such as the presence of Mn2+ or the combination
of Mn2+ and phorbol ester PMA. Moreover, pretreatment with
mAb 2A10 did not change the expression of HUTS21 epitope
relative to cells not preincubated with 2A10 under any of the
conditions tested (Ca2+/Mg2+, Mn2+, or Mn2+/PMA). Taken
together, these results indicate that the inhibitory effects caused
by the presence of CD9 or by preincubation with mAb 2A10 on
the adhesive activity of integrin α5β1 are not primarily mediated
by alterations in the ability of integrin molecules to switch to the
high affinity conformation.
We also investigated whether the observed inhibitory effects
on α5β1-mediated cell adhesion induced by the presence of CD9
are caused by changes in the organization of α5β1 molecules on
the cell surface. Double immunofluorescence staining of integrin
α5β1 and ADAM17 molecules in CD9-negative (Colo320) or
CD9-positive (Colo320-CD9) cells using mAbs specific for
integrin α5β1 (anti-β1 subunit mAb TS2/16) or ADAM17 (mAb
2A10) and analysis by confocal microscopy revealed a certain
degree of colocalization between α5β1 and ADAM17 in both
Colo320 and Colo320-CD9 cells, with Pearson’s coefficients over
0.6 (not shown). However, a different pattern of integrin and
ADAM17 distribution was observed depending on whether cells
expressed or not CD9 on the cell surface (Figure 4C), displaying
a dotty distribution in Colo320 cells and a more homogeneous
appearance on the surface of Colo320-CD9 cells. Quantitation of
the number of clusters of α5, β1 andADAM17molecules revealed
that on cells expressing CD9 (Colo320-CD9) the number of
clusters was significantly reduced, indicating that the presence of
CD9 favors the formation of larger clusters containing both α5β1
and ADAM17 molecules (Figure 4D).
The association between α5β1 and ADAM17 has been
reported to result in inhibition of the activity of both molecules.
Vice versa, the induction of the activation of either integrin α5β1
or ADAM17 causes their dissociation from the complex (6, 13).
We therefore postulated that the inhibitory effect on α5β1-
mediated cell adhesion exerted by the presence of CD9 could
be due to a reinforcement of the cis interaction between α5β1
and ADAM17 caused by this tetraspanin. If this was the case,
the inhibition of α5β1-mediated adhesion by CD9 expression,
should not be observed in the absence of ADAM17. To directly
assess this hypothesis, ADAM17 expression was knocked-out
using the CRISPR/Cas9 technique both in Colo320 and Colo320-
CD9 cells (Figure 5A). Interestingly, when ADAM17 was absent
in Colo320-CD9 cells, these cells recovered their full capacity
to adhere efficiently to both ADAM17-Fc and Fn through
integrin α5β1 (Figure 5B). In addition, the distribution of α5β1
molecules was also restored showing again an organization
in smaller and more dispersed clusters, similar in size to
those on Colo320 cells (Figure 5C). Taken together, our
results indicate that CD9 exerts an important control on both
the distribution and the adhesive capacity of α5β1 integrin
molecules.
However, clustering analysis by confocal microscopy provide
insight only about the high-order organization and subcellular
localization of molecules in the cell. To explore the organization
α5β1 integrin and ADAM17 at the plasma membrane closer
to the molecular level, we chose to use in situ Proximity
Ligation Assays (PLA), that have been previously employed
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FIGURE 3 | Ectopic expression or knocking-out of CD9 regulates α5β1-mediated cell adhesion to ADAM17-Fc and Fn. Flow cytometric detection of cell surface CD9
(mAb PAINS-10), ADAM17 (mAb 2A10), β1 (mAb TS2/16), α5 (mAb P1D6), and α4 (mAb HP2/1) on Colo320, HSB2 and Jurkat cells (A). The black dotted line
histograms correspond to negative controls, green filled histograms correspond to the expression of the indicated molecules on CD9 expressing cells (Colo320-CD9,
HSB2-CD9, Jurkat) and purple filled histograms correspond to the expression of the indicated molecules on their respective CD9-lacking counterparts (Colo320,
HSB2, Jurkat-CRISPR-CD9). The percentages of adhesion of paired variants of Colo320, HSB2 and Jurkat cells, either expressing CD9 (Colo320-CD9, HSB2-CD9,
Jurkat; green bars) or lacking expression of this tetraspanin (Colo320, HSB2, Jurkat CRISPR-CD9; black bars) on plastic-immobilized ADAM17-Fc (B) or on
fibronectin (C). In all cases, cells were stimulated with PMA (200 ng/ml) for 2 h, loaded with the fluorescent probe BCECF-AM and then allowed to adhere to
plastic-immobilized ligands ADAM17-Fc (20µg/ml) or Fn (7.5µg/ml) for 60min at 37◦C under conditions of integrin activation in the presence of Mn2+ (200µM). Data
are presented as the percentage of adhered cells (means ± SEM of three experiments each performed in triplicates). Statistical analysis was carried out using the
two-tailed paired T-test. **, *** and **** denote p < 0.01, p < 0.001 and p < 0.0001, respectively.
to demonstrate the cis interaction between ADAM17 and
integrin α5β1 (6). PLA provide positive signals (“PLA fluorescent
dots”) only if the two proteins under analysis are in close
proximity (typically <40 nm) that is compatible with a direct
interaction between them. To quantitatively analyze the effect
of CD9 expression on the α5β1/ADAM17 interactions, PLA
were performed to detect the interactions between ADAM17
and α5β1 on both Colo320 and Colo320-CD9 cells. As shown
in the images of Figure 6A, the number of PLA dots was
clearly higher on Colo320-CD9 cells and a detailed quantitative
analysis revealed a 5-fold increment in the number of dots/cell
on CD9-positive cells (Colo320-CD9) compared to CD9-negative
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FIGURE 4 | CD9-induced inhibition of integrin α5β1-mediated cell adhesion does not involve alterations of integrin affinity. (A) Flow cytometric analysis of the
expression of epitope HUTS21 in different integrin activation conditions: Ca2+/Mg2+ (0.5 mM/1mM, respectively), Mn2+ (200µM) or PMA/Mn2+ (200 ng/ml/200µM,
respectively) in Colo320 (purple-filled histograms) and Colo320-CD9 (green-filled histograms). The lower row of histograms represents the effect of cell pre-incubation
with the mAb 2A10 on the expression of HUTS21 epitope in Colo320 and Colo320-CD9 cells. The black dotted line histograms correspond to negative controls. The
fluorescence of 2,000 cells was acquired in the flow cytometer for each histogram. (B) Expression of HUTS21 epitope represented as the mean florescence intensities
from the flow cytometry histograms shown in (A). (C) Double immunofluorescence staining and confocal microscopy analysis showing the effects of CD9 expression
on the organization of integrin α5β1 (green) and ADAM17 (red) molecules on the surface of Colo320 cells. Colo320 and Colo320-CD9 cells were stained with the
anti-β1 (TS2/16) or anti-ADAM17 (2A10) mAbs. Representative images of confocal sections are shown. Scale bar = 20µm. (D) Quantitation of the number of
clusters/cell of integrin α5, β1, and ADAM17 molecules on the surface of Colo320 and Colo320-CD9. Graph shows the means ± SEM of the number of clusters/cell,
calculated from at least 350 different cells for each condition using the Image-J thresholding and particle analyses.****denotes p < 0.0001 in a one-way ANOVA with
Tukey’s post-test.
cells (Colo320; Figure 6B). As a relevant negative control
for these experiments, when ADAM17 was knocked-out in
Colo320-CD9 cells (Colo320-CD9 CRISPR-ADAM17), no PLA
dots were observed. These results provide strongly support
for the cis α5β1-ADAM17 association being enhanced on
the cell surface by the presence of CD9, probably through
the formation of ternary complexes among these molecules
(α5β1:CD9:ADAM17).
To biochemically confirm these data, we immunoprecipitated
(IP) α5β1 integrin from Colo320 and Colo320-CD9 cells using
mAb Lia1/2, which recognizes an extracellular epitope on the
β1 subunit of the integrin, and analyzed by immunobloting the
amount of co-immunoprecipitated ADAM17. Importantly, to
detect only those interactions of α5β1 and ADAM17 taking place
at the plasma membrane, we selectively precipitated only the
subset of α5β1 molecules expressed on the surface of cells by
incubating intact living cells with the anti-β1 mAb followed by
washing the excess unbound antibody prior to cell lysis and
IP. As shown in Figure 7A, mature ADAM17 (mADAM17) was
significantly more efficiently co-immunoprecipitated with α5β1
from Colo320-CD9 than from Colo320 cells, evidencing that
α5β1-ADAM17 association on the cell surface is enhanced by the
presence of CD9.
In order to directly probe the presence of CD9, ADAM17
and α5β1 in TEMs, as well as their association, we selectively
immunoprecipitated cell surface CD9 (TEM fraction) from
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FIGURE 5 | Knocking out ADAM17 reverts the CD9-mediated abrogation of α5β1-dependent cell adhesion and the alteration of α5β1 distribution on the cell surface.
(A) Flow cytometric detection of ADAM17 (mAb 2A10), CD9 (mAb PAINS-10), α5 (mAb P1D6) and β1 (mAb TS2/16) on the surface of Colo320 and Colo320-CD9
cells either expressing or lacking ADAM17 expression. The dotted black line histograms correspond to negative controls, green-filled histograms show the expression
of the indicated molecules on ADAM17-lacking cells (Colo320 CRISPR ADAM17 and Colo320-CD9 CRISPR ADAM17) and purple-filled histograms show to the
expression of the indicated molecules on Colo320 and Colo320-CD9 (ADAM17-positive cells). For each histogram the fluorescence signal of 2000 cells was acquired
in the flow cytometer. (B) Cell adhesion of ADAM17-positive and ADAM17-negative Colo320 and Colo320-CD9 cells. Cells were stimulated with PMA (200 ng/ml) for
2 h, loaded with the fluorescent probe BCECF-AM and then allowed to adhere to immobilized ligands ADAM17-Fc (20µg/ml) or Fn (7.5µg/ml) for 60min at 37◦C
under conditions of integrin activation in the presence of Mn2+ (200µM). The percentage of cells that remained adhered is indicated as mean ± SEM. Statistical
analysis performed was one-way ANOVA and Tukey’s multiple comparison test. *p < 0.05, **p < 0.01, ***p < 0.001. (C) Immunofluorescence staining and confocal
microscopy analysis of α5β1 integrin molecules organization on the surface of ADAM17-positive and ADAM17-negative Colo320 and Colo320-CD9 cells. α5β1
molecules were stained with the anti-β1 (TS2/16) mAb. Representative images of confocal microscopy sections are shown. Scale bar = 20µm. Lower panel:
Quantitation of the area of integrin α5β1 clusters in square micrometers on the surface of the different types of cells. Graph depicts the means ± SEM of cluster areas
calculated from 800-3000 different cells using the Image J software. ****denotes p < 0.0001 in a one-way ANOVA with Šidák’s post-test.
intact Colo320-CD9 cells and detected the amount of co-
immunoprecipitated α5β1 and ADAM17. Figure 7B shows that
when IP of cell surface CD9 was performed in the presence
of extracellular Ca2+ and Mg2+, α5β1 and ADAM17 were
efficiently co-immunoprecipitated. Interestingly, induction of
conformational changes in α5β1 by the presence of Mn2+
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FIGURE 6 | Effects of the expression of CD9 on the cis interactions between integrin α5β1 and ADAM17. (A) Analysis by in situ proximity ligation assays (PLA) of the
molecular association of ADAM17 with integrin α5β1 on cells expressing CD9 (Colo320-CD9, middle image) or not (Colo320, top image). Cells expressing CD9 but
lacking ADAM17 (Colo320-CD9/CRISPR-ADAM17, bottom image) were included as an internal negative control for ADAM17-α5 association. Scale bars = 20µm.
Sketches on the right summarize the principle of PLA. (B) The graph represents the mean ± SEM of the number of PLA dots/cell calculated from at least 100 cells (for
each cell line) from different micrographic fields in two different experiments and analyzed by one-way ANOVA with Tukey’s post-test analysis. ****p < 0.0001.
resulted in lower amounts of co-immunoprecipitated α5β1 and
ADAM17 indicating that, in even in the presence of CD9, some
degree of dissociation of these molecules takes place when the
integrin conformation is altered.
DISCUSSION
Integrin α5β1, also named VLA5 or CD49e/CD29, is a major
cellular receptor for the extracellular matrix protein fibronectin
(Fn) [reviewed in (40)]. As such, this integrin is crucial for cell
adhesion to the extracellular matrix and is also critically involved
inmany cell signaling andmigration phenomena, with important
implication in tumor invasion and progression (41, 42). Integrin
α5β1 binds to its canonical ligand Fn through recognition of
the Arg-Gly-Asp (RGD) motif in Fn-type-III module 10 as well
as a synergy site in Fn-type-III module 9, contributing to the
assembly of Fn molecules into fibrils (4, 43). In addition to
binding to its canonical ligand Fn, integrin α5β1 has more
recently been reported by different groups to bind specifically to
the disintegrin domain of the transmembrane metalloproteinase
ADAM17 (5–7, 13). These interactions of α5β1 with ADAM17
can occur between molecules expressed on the same cell (cis
interactions) or on different cells (trans interactions). The
α5β1-ADAM17 interactions have been investigated in some
detail, both in in vitro cell free assays through employment
of recombinant proteins (5, 6) and also in cellular assays
which collectively confirmed that these interactions support
intercellular adhesion, such as the one taking place between
tumor and fibroblastic cells (7, 13). Interestingly, in those
cell free studies it was observed that the direct interaction
between ADAM17 and integrin α5β1 molecules resulted in
inhibition of ADAM17 proteolytic activity (6). In cellular
experiments with kidney mesangial cells it was established
that β1 integrin silencing caused an increase in ADAM17
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FIGURE 7 | Cell surface ADAM-17 is more efficiently co-immunoprecipitated with integrin α5β1 from Colo320-CD9 cells than from Colo320 cells. (A) Only cell surface
integrin α5β1 molecules were selectively immunoprecipitated by incubating the cells with mAb Lia1/2 (anti-β1) in the presence of Ca
2++Mg2+ (500µM each) and
washing the excess non-bound antibody prior to cell lysis and immunoprecipitation. Immunoprecipitated integrin α5β1 and co-immunoprecipitated ADAM17 were
detected by immunoblotting with the anti-β1 (TS2/16) and anti ADAM17 (A300D) mAbs, respectively. The gel shown is representative of five different experiments. The
graph below shows the densitometric quantitation of the amount of precipitated integrin and co-immunoprecipitated ADAM17 (means ± SEM) from five different
experiments, normalized to β1 precipitated in Colo320 cells in each experiment. (B) Integrin α5β1 and ADAM17 are coimmunoprecipitated with CD9 from cell surface
TEMs. CD9 was immunoprecipitated with mAb PAINS10 as described for integrin β1 in (A) but under two different extracellular cation conditions: in the presence of
Ca2++Mg2+ (500µM each) or Mn2+ (200µM). Immunoprecipitated CD9 and co-immunoprecipitated β1 and ADAM17 were detected by immunoblotting with mAbs
PAINS10 (anti-CD9), TS2/16 (anti-β1), and A300D (anti ADAM17), respectively. The gel shown is representative of four different experiments. The graph below
represents the densitometric quantitation of the amount of precipitated CD9 and co-immunoprecipitated integrin β1 and ADAM17 (means ± SEM) normalized to the
immunoprecipitated CD9 in each of the four independent experiments. Statistical analysis was carried out using two-tailed paired T-test. *p < 0.05, **p < 0.01,
***p < 0.001.
sheddase activity whereas β1 integrin overexpression resulted in
reduced ADAM17 activity (6), confirming the inhibitory role of
integrin α5β1 on ADAM17 activity in living cells. Noteworthy,
in these studies stimulation of integrin α5β1 with divalent
cation Mn2+, a potent activator of integrins which induces
their extended and open headpiece high-affinity conformation,
brought about the dissociation of the α5β1-ADAM17 complex
with a concomitant increase in ADAM17 sheddase activity. Thus,
it was concluded that it is the inactive form of the integrin α5β1
which becomes selectively engaged in direct interactions with
ADAM17, thus keeping low the metalloproteinase activity of this
enzyme.
While the functional consequences on ADAM17 shedding
activity derived from its association with α5β1 have been
investigated, no reports have addressed so far the effects of
those interactions on integrin α5β1 adhesive activity. Thus, in
the present study we have focused on the functional outcome
brought about by treatment with mAb 2A10 (which is directed
to the disintegrin domain of human ADAM17) or expression
of the tetraspanin CD9, on the adhesive capacity the integrin
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α5β1. We have demonstrated that treatment with mAb 2A10
or expression of CD9 on the cell surface specifically abrogates
the α5β1-mediated adhesion of different types of tumor and
leukocytic cells both to its canonical ligand Fn and also to its
alternative ligand ADAM17-Fc, a recombinant protein which
encompasses all the domains of the extracellular region of
human ADAM17 (pro-, catalytic-, disintegrin- and membrane
proximal-domain) fused to the Fc constant region of human
IgG. Previous reports have shown that α5β1-dependent cell
adhesion to its ligand ADAM17 is specifically supported by
the disintegrin domain of this recombinant protein (5, 7,
13). The fact that mAb 2A10, specific for the disintegrin
domain of ADAM17, not only inhibits the α5β1-mediated
adhesion of Colo320 and K562 cells to ADAM17-Fc, but also
to Fn, suggests that 2A10 mAb, similarly to CD9 expression,
could enhance the cis ADAM17-α5β1 interactions on the cell
surface.
Integrin adhesive capacity is regulated mainly by two
alternative and often complementary mechanisms involving, on
the one hand, alterations in the conformation of individual
integrin molecules that are reflected by changes in affinity,
and on the other hand, modifications in the aggregation and
organization of integrin molecules which affect their multivalent
avidity for ligands (2, 44, 45). Thus, one possibility to explain
the inhibition of α5β1-mediated cell adhesion that is brought
about by the expression of CD9 could be that this tetraspanin
prevents the acquisition of the extended and open headpiece
(i.e., the high affinity) conformation of this integrin. Our results
showing that the expression of the HUTS21 epitope is not
affected by the presence of CD9 under any of the stimulation
conditions tested seem to rule out this possibility. An alternative
possibility to account for the observed inhibition of α5β1-
mediated cell adhesion is that expression of CD9 produces
changes in the organization of integrin molecules on the cell
surface that would account for a reduction in integrin avidity.
Our confocal microscopy analyses of immunofluorescently-
stained integrin α5β1 and ADAM17 show that the pattern of
distribution of this integrin is affected both by the expression
of CD9 and of ADAM17. Thus, on CD9-negative Colo320
cells integrin α5β1 and ADAM17 molecules are distributed
in a high number of small discrete clusters, while upon
CD9-expression the localization is somewhat more continuous
and the number of clusters per individual cell is reduced.
Furthermore, when ADAM17 was knocked-out in Colo320-
CD9, α5β1 regained the dotted pattern, correlating with a
recovery of the adhesion capacity. However, although interesting,
the analyses of the overall distribution of α5β1 and ADAM17
at the plasma membrane by confocal microscopy are limited
by the resolution limit of the technique and thus, provide
limited insight of the detailed molecular environment of each
receptor.
Using a combination of different approaches, including
in situ proximity ligation assays (PLA), immunofluorescence
staining followed by confocal microscopy and biochemical co-
immunoprecipitation experiments, we have established that
tetraspanin CD9 inhibits α5β1-mediated cell adhesion by
reinforcing the cis association between ADAM17 and integrin
α5β1 on the cell surface. In situ PLA have been previously
employed by Gooz et al. to confirm and quantitatively assess
the strength of the interaction between ADAM17 and integrin
α5β1 (6). This technique provides positive signals only when
two molecules are in close proximity, typically<40 nm, implying
a direct molecular interaction. We have employed PLA to
quantitatively analyze the effect of CD9 expression on the
association between α5β1 and ADAM17 and our results clearly
show that the number of PLA fluorescent dots was significantly
higher in CD9-positive than in CD9-negative cells, indicating
that the cis α5β1-ADAM17 association on the cell surface is
enhanced by the presence of CD9. Interestingly, when expression
of ADAM17 is knocked-out, CD9 is no longer capable to abrogate
integrin α5β1-mediated cell adhesion, strongly pointing out to
the formation of trimolecular α5β1:CD9:ADAM17 complexes
as the mechanism behind the regulation of both the adhesive
activity of α5β1 and the shedding function of ADAM17 by
tetraspanin CD9.
Gooz et al. also performed co-immunoprecipitation
experiments to confirm the association of integrin α5β1
and ADAM17 (6) and showed that stimulation with extracellular
manganese ions (Mn2+), a potent inducer of integrin activation
(2, 31, 44, 46), decreased the association of these two molecules.
We performed co-immunoprecipitation experiments to assess
both the influence of CD9 expression and that of integrin
activation (under different divalent cations conditions) on the
association of α5β1 with ADAM17 molecules selectively on the
cell surface. Our immunoprecipitation data clearly show that
expression of CD9 greatly enhances the association between
α5β1 and ADAM17. Upon integrin activation with Mn2+ the
amount of α5β1 and ADAM17 that co-immunoprecipitates with
CD9 is reduced, but not completely abolished. These biochemical
results, together with the PLA data, confirm that expression of
CD9 reinforces cis interactions of α5β1 and ADAM17 on the
cell surface highlighting a dominant role for tetraspanin CD9
in regulating the adhesive activity of integrin α5β1 through a
reinforcement of the α5β1-ADAM17 association on the cell
surface.
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Supplementary Figure 1 | The adhesion of HSB2 and Jurkat lymphocytic cell
lines to plastic-immobilized ICAM-1-Fc is not affected by the presence of mAb
2A10. Cell adhesion to ICAM-Fc is mediated specifically by the integrin LFA-1
(αLβ2), which is only expressed on some leukocytic cells, including HSB2 and
Jurkat cells, but not on K562 or Colo320 cells. In all cases, cells were stimulated
with PMA (200 ng/ml) for 2 h, loaded with the fluorescent probe BCECF-AM and
then allowed to adhere to plastic-immobilized ligand ICAM1-Fc (20µg/ml) for
60min at 37◦C in the presence of Mn2+ (200µM). Data show the percentage of
adhered cells (means ± SEM of three experiments, performed in triplicates). mAb
2A10 did not exert any statistically significant effect on the LFA-1 mediated cell
adhesion to ICAM1-Fc for any of the cell lines as analyzed by two-tailed paired
T-tests.
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